Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma

A discussion between an oncologist and a patient, Evelyn, a transgender woman with prostate cancer who was able to change the doctor’s binary view of gender thanks to a candid conversation and the help from a dozen eggs – brown and blue.

An OBGYN voices frustration — “silently cursing behind my mask” – with the patients who “recite a litany of scientifically illiterate reasons for not taking” the COVID-19 vaccine despite its 99%+ effectiveness in keeping them alive. Do you share this doctor’s sentiments?

Research shows that the “old” 2015 recommendation would only identify about half of Americans with prediabetes and undiagnosed type 2 diabetes. Based on this data, the US Preventive Services Task Force has lowered the recommended screening age from 40 to 35 years in asymptomatic, nonpregnant adults who are overweight or obese.

This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.

An oncologist pens an essay about his 10-year-old son who died in March 2021 from diffuse midline glioma, providing a glimpse into his own extreme truths about the burden he carries in treating cancer patients.